BRAF in metastatic colorectal cancer: the future starts now

被引：14

作者：

Orlandi, Armando ^{[1
]}

Calegari, Maria Alessandra ^{[1
]}

Inno, Alessandro ^{[2
]}

Berenato, Rosa ^{[3
]}

Caporale, Marta ^{[3
]}

Niger, Monica ^{[3
]}

Bossi, Ilaria ^{[3
]}

Di Bartolomeo, Maria ^{[3
]}

de Braud, Filippo ^{[3
]}

Pietrantonio, Filippo ^{[3
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[2] Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 18期

关键词：

BRAF; colorectal cancer; immunotherapy; target therapy; FOLFOXIRI PLUS BEVACIZUMAB; EGFR MONOCLONAL-ANTIBODIES; KRAS MUTATIONAL STATUS; COLON-CANCER; V600E MUTATION; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; RAS MUTATIONS; POOR SURVIVAL; MAPK PATHWAY;

D O I：

10.2217/pgs.15.140

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

引用

页码：2069 / 2081

页数：13

共 50 条

[21] Concomitant BRAF and RAS Mutations in Metastatic Colorectal Cancer
Srivastav, Jigisha
Lima, Caio Rocha
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S309 - S310
[22] Our green future starts now
Marshall, Michael
Aldhous, Peter
NEW SCIENTIST, 2013, 219 (2924) : 6 - 7
[23] For wireless USB, the future starts now
Leavitt, Neal
COMPUTER, 2007, 40 (07) : 14 - 16
[24] The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future
Djanani, Angela
Eller, Silvia
Ofner, Dietmar
Troppmair, Jakob
Maglione, Manuel
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 21
[25] Precision treatment in colorectal cancer: Now and the future
Yau, Tung On
JGH OPEN, 2019, 3 (05): : 361 - 369
[26] Screening for colorectal cancer - Now and the near future
Bromer, MQ
Weinberg, DS
SEMINARS IN ONCOLOGY, 2005, 32 (01) : 3 - 10
[27] Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
Takeda, Hiroyuki
Sunakawa, Yu
FRONTIERS IN ONCOLOGY, 2021, 11
[28] Latest Advance to Clinical Development and Future Perspective for RAS/BRAF-mutated Metastatic Colorectal Cancer
Yoshino, Takayuki
ANNALS OF ONCOLOGY, 2016, 27
[29] BRAF V600E mutated metastatic colorectal cancer: current progress and future directions
Kam, Audrey E.
Eng, Cathy
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (10) : 1311 - 1313
[30] Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, John H.
Wu, Christina
Bekaii-Saab, Tanios
CANCER TREATMENT REVIEWS, 2017, 60 : 109 - 119

← 1 2 3 4 5 →